Verenium Corporation Management Discusses Q4 2010 Results - Earnings Call Transcript
Before we begin, I would like to advise you that this discussion will include forward-looking statements within the meaning of Section 27A of the Securities Exchange Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements involve a high degree of risk and uncertainty and relate to matters such as our strategy, future operating plans, markets for our products, partnering, collaboration activities, public policy and financing activities, technical and business outlooks.
Such statements are only predictions, and actual events or results may differ materially from those projected in such forward-looking statements. Factors that could cause or contribute to differences include, but are not limited to, risks related to our IP partners, competitors, and regulatory market forces. Certain of these factors and others are more fully described in our filings with the SEC, included, but not limited to, our report on Form 10-Q for the quarter ended September 30, 2010. These forward-looking statements speak only as of the date hereof, and company expressly disclaims any intent or obligation to update these forward-looking statements.
I will now turn the call over to Jamie.
James LevineThanks, Kelly and good afternoon everyone and thank you for joining us on today's call. I'd like to begin by discussing the organizational changes we announced last week. As a recap, I will be stepping into the role of President and Chief Executive Officer succeeding Carlos and Jeff Black has been promoted to Chief Financial Officer. Janet Roemer remains Verenium's Chief Operating Officer.I’m extremely enthusiastic about taking on this new role and look forward to continuing to partner with Janet, Jeff and the rest of the team here at Verenium. For the last couple of years, I’ve had the chance to work closely with a knowledgeable, energetic and hard working people at Verenium and I'm honored to work with a team of this caliber to continue building what is the potential to be the next leading industrial enzyme’s company.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV